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Abstract: Many women who experience gestational diabetes (GDM), gestational hypertension (GHT),
pre-eclampsia (PE), have a spontaneous preterm birth (sPTB) or have an offspring born small/large
for gestational age (SGA/LGA) do not meet the criteria for high-risk pregnancies based upon certain
maternal risk factors. Tools that better predict these outcomes are needed to tailor antenatal care
to risk. Recent studies have suggested that metabolomics may improve the prediction of these
pregnancy-related disorders. These have largely been based on targeted platforms or focused on a
single pregnancy outcome. The aim of this study was to assess the predictive ability of an untargeted
platform of over 700 metabolites to predict the above pregnancy-related disorders in two cohorts. We
used data collected from women in the Born in Bradford study (BiB; two sub-samples, n = 2000 and
n = 1000) and the Pregnancy Outcome Prediction study (POPs; n = 827) to train, test and validate
prediction models for GDM, PE, GHT, SGA, LGA and sPTB. We compared the predictive performance
of three models: (1) risk factors (maternal age, pregnancy smoking, BMI, ethnicity and parity) (2)
mass spectrometry (MS)-derived metabolites (n = 718 quantified metabolites, collected at 26–28 weeks’
gestation) and (3) combined risk factors and metabolites. We used BiB for the training and testing of
the models and POPs for independent validation. In both cohorts, discrimination for GDM, PE, LGA
and SGA improved with the addition of metabolites to the risk factor model. The models’ area under
the curve (AUC) were similar for both cohorts, with good discrimination for GDM (AUC (95% CI)
BiB 0.76 (0.71, 0.81) and POPs 0.76 (0.72, 0.81)) and LGA (BiB 0.86 (0.80, 0.91) and POPs 0.76 (0.60,
0.92)). Discrimination was improved for the combined models (compared to the risk factors models)
for PE and SGA, with modest discrimination in both studies (PE-BiB 0.68 (0.58, 0.78) and POPs 0.66
(0.60, 0.71); SGA-BiB 0.68 (0.63, 0.74) and POPs 0.64 (0.59, 0.69)). Prediction for sPTB was poor in BiB
and POPs for all models. In BiB, calibration for the combined models was good for GDM, LGA and
SGA. Retained predictors include 4-hydroxyglutamate for GDM, LGA and PE and glycerol for GDM
and PE. MS-derived metabolomics combined with maternal risk factors improves the prediction of
GDM, PE, LGA and SGA, with good discrimination for GDM and LGA. Validation across two very
different cohorts supports further investigation on whether the metabolites reflect novel causal paths
to GDM and LGA.
Keywords: prediction; pregnancy; metabolomics; metabolites; mass spectrometry
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1. Introduction
Gestational diabetes (GDM), gestational hypertension (GHT), pre-eclampsia (PE),
small for gestational age (SGA), large for gestational age (LGA) and spontaneous preterm
birth (sPTB) are common pregnancy-related disorders [1–7]—associated with long-term
mortality and morbidity in mother and offspring [7–10]. Currently, the prediction of
these disorders relies largely on stratifying women based on established risk factors. The
established risk factors for predicting these disorders include maternal smoking [11],
age [12], ethnicity [13], parity [14] and body mass index (BMI) [15]. However, many women
do not meet any of these risk factors and yet go on to have a complicated pregnancy [16–18].
A good indicator of risk is previous pregnancy history. However, this is not obtainable in
nulliparous women [19,20], and there is a need for clinical prediction models that do not
depend on previous pregnancy history [19]. Development of such might result in better
ways of managing antenatal care by intensely monitoring higher risk women and avoiding
unnecessary intervention in low-risk women.
Pregnancy is characterised by widespread metabolic changes [21–23]. Metabolomics,
the quantification of molecules arising from metabolic processes, could improve the predic-
tion of common pregnancy-related disorders [24]. We have recently shown that a targeted
nuclear magnetic resonance (NMR)-derived metabolomics panel of 156 (mostly lipid) traits
can improve the prediction of GDM, LGA and hypertensive disorders of pregnancy (HDP)
in Born in Bradford (BiB), a large general population pregnancy cohort. This work was
externally validated in the UK Pregnancies Better Eating and Activity trial (UPBEAT), a
cohort of obese pregnant women [25]. We have also identified novel metabolite predictors
for specific pregnancy outcomes using a mass spectrometry (MS)-derived metabolites
platform in the Pregnancy Outcome Prediction study (POPs), which were externally vali-
dated in the BiB cohorts. Specifically, we found that the amino acid 4-hydroxyglutamate
improves the prediction of PE in term pregnancy. A ratio of the product of the plasmalogen
1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-18:0/18:1) and the steroid 5α-androstan-3α,17α-diol
disulfate to the product of the carbohydrate 1,5-anhydroglucitol and the polyamine N1,N12-
diacetylspermine was a better predictor of fetal growth restriction/SGA than the clinically
validated biomarker soluble fms-like tyrosine kinase 1 and placental growth factor ratio
(sFlt:PlGF) [26,27]. In the previous studies, we used serial samples from POPs, and the
focus was identifying a small number of independently predictive metabolites that might
form the basis of a targeted assay. However, these ratios do not form part of the analysis
of this paper. In this paper, we use the entire MS metabolomic profile and an elastic net
approach, with models developed in one cohort and validated in another.
To date, most studies have focused on a narrow range of metabolites and/or on a
single pregnancy outcome, lack external validation and suffer from overfitting. The aim of
this study is to determine whether metabolites included in an extensive MS metabolomics
platform can improve the prediction of six common pregnancy outcomes (GDM, PE, GHT,
SGA, LGA and sPTB) over established risk factors alone. Here, we validate the results
externally and show metabolomics enhances prediction over maternal characteristics
risk factors alone. The multimorbidity that exists between these disorders may mean a
prediction tool for more than one could be clinically valuable. We therefore compare the
overlap between traits across the prediction models for each outcome and whether a single
prediction model can be developed to predict the occurrence of any of the six outcomes.
2. Results
The BiB 1000 and BiB 2000 sub-samples have similar distributions of age, BMI, parity
and smoking, and, by design, both are around half White British and half Pakistani
(Table 1). In contrast, around 95% of the POPs women studied are of White ethnicity. The
BiB 1000 and BiB 2000 have higher smoking prevalence than POPs. BiB is a cohort of both
multiparous and nulliparous women, whereas POPs is all nulliparous women.
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Table 1. Participant characteristics from the three participating cohorts: Born in Bradford 2000, Born in Bradford 1000 and
the Pregnancy Outcome Prediction study.





(case/comparator) or n (%) 245/1350 84 (9.2) 172/295
Gestational hypertension
(case/comparator) or n (%) 217/1375 64 (7.0) 6/300
Pre-eclampsia
(case/comparator) or n (%) 74/1494 24 (2.6) 175/286
Large for gestational age
(case/comparator) or n (%) 76/1425 37 (4.0) 12/294
Small for gestational age
(case/comparator) or n (%) 260/1275 102 (11.1) 188/279
Spontaneous preterm birth
(case/comparator) or n (%) 87/1441 21 (2.3) 98/297
BMI kg/m2 (mean (SD)) 26.8 (5.8) 26.7 (6.0) 26.0 (5.3)
Age (mean years) 27.5 (5.6) 27.4 (5.7) 30.3 (5.3)
Pregnancy smoking, n (%) 378 (18.9) 159 (17.4) 119 (14.4)
Multiparous, n (%) 1213 (60.7) 581 (63.5) 0 (0)
White ethnicity, n (%) 933 (46.7) 456 (49.8) 787 (95.2)
Data in this table are complete. BiB 2000 and POPs used a case cohort design, i.e., they were over-sampled for cases. In these two studies,
the total numbers vary depending on the outcome. For the distributions of risk factor predictors in this table, we used the overall mass
spectrometry sample cohorts, n = 2000 for BiB 2000 and n = 827 for POPs (Figure S1). Because of substantial oversampling of cases in
these studies, we do not give a prevalence (%) for the outcomes but rather give the numbers of cases and number in the comparison
group for each outcome. The number of women in the comparator group varies per outcome, as some from the comparator group are
always relabelled as cases. POPs did not have an adequate number of women with GHT; hence, no validation analysis was performed.
Abbreviations: BMI, body mass index.
Table 2 shows the number of predictors retained in each model during model training
in BiB 2000. Of the total 723 predictors included in the combined risk factor (n = 5) and
metabolites (n = 718) model, most were retained in the sPTB model and least in the GDM
model. At least four of the five established risk factors were retained in the risk factor
models for all outcomes except SGA. A full list of the retained predictors is available in
Tables S5–S10.
We found little overlap between the predictors retained in the combined risk factor and
metabolite models across outcomes. There was an overlap of 41 predictors in the combined
models for the GDM and LGA models, including 4-hydroxyglutamate, which was also
retained for PE. There were five predictors retained in both the combined GDM and PE
models, including 4′hydroxyglutamate and glycerol. There were 33 predictors retained for
both LGA and SGA, including lanthionine, pipecolate, BMI, ethnicity and parity.
In both BiB and POPs cohorts, discrimination for GDM, PE, LGA and SGA improved
with the addition of metabolites to the risk factor only model (combined model). The
combined model AUC’s were similar for both cohorts, with good discrimination for GDM
and LGA (GDM-(AUC (95% CI)) BiB 0.76 (0.71, 0.81) and POPs 0.76 (0.72, 0.81); LGA-BiB
0.86 (0.80, 0.91) and POPs (0.76 (0.60, 0.92)). Discrimination was improved for the combined
models compared to the risk factors for PE and SGA, but the AUC was modest (PE-BiB
0.68 (0.58, 0.78) and POPs 0.66 (0.60, 0.71); SGA-BiB 0.68 (0.63, 0.74)) and POPs (0.64 (0.59,
0.69)). In BiB, risk factors alone were the best predictor of GHT: 0.74 (0.68, 0.80) compared
to 0.72 (0.66, 0.79) for the combined model. The GHT models could not be validated in
POPs due to an inadequate number of cases with metabolite data. Discrimination for sPTB
was very poor for all models and in both cohorts, with a negligible improvement in the
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BiB 1000 testing set with the addition of metabolites to the risk factors model (0.54 (0.40,
0.67) increasing to 0.56 (0.45, 0.67)) (Figure 1). In POPs, the AUC was 0.50 for both models
(Table S4).
Table 2. Number of predictors retained in each model developed and tested in BiB 2000 from total possible (n (%)).
Percentages are rounded to the nearest whole number.
Outcome Model (Retained Predictors/Total Number of Predictors Possible (%))
Gestational diabetes








Risk factor (4/5 (80%))
Metabolite (154/718 (21%))
Combined (28/723 (4%))
Small for gestational age
Risk factor (5/5 (100%))
Metabolite (66/718 (9%))
Combined (65/723 (8%))
Large for gestational age




Risk factor (4/5 (80%))
Metabolite (587/718 (83%))
Combined (328/723 (45%))
Calibration slopes showed good adherence of the predicted probabilities to the ob-
served outcomes for the combined metabolite and risk factor models for GDM and SGA.
Calibration was moderate for LGA. There was overestimation for GDM and underesti-
mation for SGA and LGA as the intercepts show below (Figures 2–4). Calibration was
attenuated for the models in POPs (Figures S3–S5). Calibration for the other outcomes was
poor (Figures S2, S6 and S7).
Additional Analyses
In an additional analysis of all PTB in BiB (141/1441 cases in BiB 2000 training and
38/915 cases in BiB 1000 testing), results did not differ substantially from those for just
sPTB (87/1441 cases in BiB 2000 training and 21/915 cases in BiB 1000 testing), with poor
discrimination (Table S12).
There were 828 women with ‘any’ pregnancy-related disorder in the BiB 2000 (training)
and 301 with ‘any’ pregnancy-related disorder in the BiB 1000 (testing). The combined
risk factors and metabolite model had very moderate discrimination, with an AUC for
predicting ‘any’ pregnancy-related of 0.62 (0.58, 0.66). This is only a slight improvement on
the discrimination for the clinical risk factor model 0.60 (0.56, 0.64). It did have good model
calibration (Figure S7). The retained predictors include those retained in the models for
GDM, PE and LGA, including glutamate, 4-hydroxyglutamate, glycerol and the nucleotide
5,6-dihydrouracil (Table S11).
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Figure 1. Predictive discrimination of models for each outcome. AUC and 95% confidence intervals are shown for estab-
lished risk factor prediction models (red), metabolite models (green) and combined risk factor and metabolite models 
(yellow) trained in the Born in Bradford 2000, tested in the Born in Bradford 1000 (triangles) and externally validated in 
the Pregnancy Outcome Prediction study (circles). POPs did not have sufficient data on gestational hypertension for val-
idation. Abbreviations: BiB, Born in Bradford; POPs, Pregnancy Outcome Prediction study; GDM, gestational diabetes; 
GHT, gestational hypertension; PE, pre-eclampsia; SGA, small for gestational age; LGA, large for gestational age; sPTB, 
spontaneous preterm birth. 
Figure 1. Predictive discrimination of odels for each outcome. AUC and 95% confidence intervals
are shown for established risk factor prediction models (red), metabolite models (green) and combined
risk factor and metabolite models (yellow) trained in the Born in Bradford 2000, tested in the Born
in Bradford 1000 (triang es) and externally validated in the Pre nancy Outcome Prediction study
(circles). POPs did not have sufficient data on gestational hypertension for validation. Abbreviations:
BiB, Born in Bradford; POPs, Pregnancy Outcome Prediction study; GDM, gestational diabetes;
GHT, gestational hypertension; PE, pre-eclampsia; SGA, small for gestational age; LGA, large for
gestational age; sPTB, spontaneous preterm birth.




Figure 2. Calibration slope for GDM combined model in BiB 1000 testing sample. 
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Figure 4. Calibration slope for SGA combined model in BiB 1000 testing sample. 
Additional Analyses 
In an additional analysis of all PTB in BiB (141/1441 cases in BiB 2000 training and 
38/915 cases in BiB 1000 testing), results did not differ substantially from those for just 
sPTB (87/1441 cases in BiB 2000 training and 21/915 cases in BiB 1000 testing), with poor 
discrimination (Table S12). 
There were 828 women with ‘any’ pregnancy-related disorder in the BiB 2000 (train-
ing) and 301 with ‘any’ pregnancy-related disorder in the BiB 1000 (testing). The combined 
risk factors and metabolite model had very moderate discrimination, with an AUC for 
predicting ‘any’ pregnancy-related of 0.62 (0.58, 0.66). This is only a slight improvement 
on the discrimination for the clinical risk factor model 0.60 (0.56, 0.64). It did have good 
model calibration (Figure S7). The retained predictors include those retained in the models 
for GDM, PE and LGA, including glutamate, 4-hydroxyglutamate, glycerol and the nu-
cleotide 5,6-dihydrouracil (Table S11). 
3. Discussion 
In this study, we showed improved prediction for GDM and LGA using a model that 
combines mass spectrometry-assessed metabolites and risk factor predictors compared to 
established predictors only. We also found improved prediction of PE and SGA in the 
testing and external validation cohorts—but for these outcomes, discrimination was mod-
est. These models were tested and externally validated in two independent cohorts. The 
BiB cohort is largely socioeconomically deprived (68% living in an area of the highest 
quintile of socioeconomic deprivation in England), includes women of different ethnici-
ties and is ~40% nulliparous. POPs is more affluent (0% living in an area of the highest 
quintile of socioeconomic deprivation in England)(26), the majority are White women 
(~95% in this study) and all women are nulliparous. The validation of the models trained 
Figure 4. Calibration slope for SGA combined model in BiB 1000 testing sample.
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3. Discussion
In this study, we showed improved prediction for GDM and LGA using a model that
combines mass spectrometry-assessed metabolites and risk factor predictors compared
to established predictors only. We also found improved prediction of PE and SGA in
the testing and external validation cohorts—but for these outcomes, discrimination was
modest. These models were tested and externally validated in two independent cohorts.
The BiB cohort is largely socioeconomically deprived (68% living in an area of the highest
quintile of socioeconomic deprivation in England), includes women of different ethnicities
and is ~40% nulliparous. POPs is more affluent (0% living in an area of the highest quintile
of socioeconomic deprivation in England)(26), the majority are White women (~95% in this
study) and all women are nulliparous. The validation of the models trained and tested in
BiB in POPs suggest the models are not influenced by overfitting and are generalisable
across diverse populations.
Calibration was good for the combined risk factor and metabolite model for GDM and
SGA, and it was moderate for LGA. Calibration was consistently attenuated in the POPs
validation. This would be expected, as the key determinant of calibration is the prevalence
of the outcome in the underlying population, and re-calibration (by modifying the model
intercept based on population prevalence whilst keeping all other parameters the same) is
often used when comparing models between populations. We would therefore expect the
calibration to be better in BiB 1000 than POPs, as it is from the same underlying population
as BiB 2000. The marked differences between POPs and BiB in socioeconomic background,
ethnicity and parity would contribute to making outcome prevalence very different. The
risk factor model validation of LGA and SGA performed particularly poorly in POPs. This
may be explained by participant characteristic differences between the two cohorts, such
as ethnicity. Ethnicity is a good predictor of these outcomes in BiB. In the observational
analyses in POPs, there is no association between ethnicity and LGA and SGA, possibly
due to very little variation in ethnicity in POPs (with 95% of women being White).
Due to the known overlap in pregnancy-related disorders, we trained (BiB 2000)
and tested (BiB 1000) the prediction models for ‘any’ pregnancy-related disorder. The
discrimination for the combined prediction model was modest and not much improved
from the risk factors model. This suggests that a single metabolomic prediction tool for
‘any’ pregnancy complication is unlikely to be feasible, despite the fact that calibration
was good.
In our previous work, we found that NMR-derived metabolomics improves upon risk
factors for the prediction of GDM, LGA, SGA and combined PE and GHT (hypertensive
disorders of pregnancy—HDP). We reported the best discrimination for GDM and LGA,
and our findings here suggest that metabolites from different platforms are valuable
for the prediction of GDM and LGA [25]. In previous work in POPs and BiB 1000, we
found that the amino acid 4-hydroxyglutamate was a novel predictor of PE, and the
metabolite ratio described above was a better predictor of fetal growth restriction/SGA
than a biomarker ratio used in the diagnosis of PE (sFlt1:PlGF) [27,28]. The focus of these
previous studies was to identify a small number of independently predictive metabolites
to be used in a targeted assay. The aim of this study was to evaluate predictive associations
with a metabolomic profile using an optimised model development approach, elastic net.
Therefore, the ratios were not used in this study.
The consistency in observations across the two distinct cohorts implies that some of
these metabolites might be causal in determining the pregnancy complications studied.
Consistent with our earlier published work, 4-hydroxyglutamate was one of the metabolites
maintained in the combined model for PE in the new BiB 2000 cohort. 4′hydroxyglutamate
was also retained in the combined models for GDM, LGA and in the ‘any’ pregnancy-related
disorder combined model. The lipid glycerol was a retained predictor for GDM, PE and the
‘any’ pregnancy-related disorder combined model. These represent potential markers for
future study. Despite these individual metabolites being maintained in prediction models
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for more than one outcome, overall, there was relatively little overlap between the retained
models where we had good prediction for different pregnancy-related disorders.
These findings suggest that metabolites (from different platforms) contribute to the
improved prediction of GDM, LGA, SGA and PE compared to the models using only estab-
lished maternal risk factors. Whilst some studies have also shown value in metabolomics
for predicting PTB, most of those have small sample sizes, have not compared predictive
ability to established risk factors or not externally validated findings [29–31]. Our work,
with external validation, suggests that PTB is not accurately predicted by established risk
factors, metabolomic profile or the two combined.
The key strengths of this study are the internal and external (independent) validation
and the exploration of a very large number of metabolite measures. We assessed the
discrimination and calibration of our prediction models and found using metabolomics
improved performance compared to established risk factors for GDM, PE, LGA and SGA.
MS has the advantage of giving greater coverage of the metabolome than other methods
such as NMR; however, it is more expensive (~150 GBP a sample as opposed to ~25 GBP a
sample). Due to this, it is hard to find any other cohorts currently with MS data generated
in pregnancy samples to strengthen our findings. None of these datasets represented
random samples; therefore, future work should continue to validate these models in more
general populations.
Despite trying to harmonise data between BiB and POPs, there were some differences
in outcomes between the two. POPs performed metabolomics on a subset of cases of PE
with more severe PE and excluded women with non-severe superimposed term PE from
the case definition in the case-cohort design. There were only 12 cases of LGA in the POPs
case-cohort, as LGA was not one of the outcomes of interest in the original case-cohort
analysis. Therefore, the estimates have wide confidence intervals. In BiB 2000, we included
any PTB as cases, whereas in POPs, the case definition included sPTB only. Therefore,
we used sPTB in the main analysis, which included both BiB and POPs. However, it is
reassuring that the results are consistent between the two studies. Whilst PE is the more
severe form of HDP, GHT affects more women and is also associated with adverse perinatal
and longer term outcomes. Independent external validation of the GHT model is important
but could not be performed in POPs since GHT was not included in the case-cohort design
in this population.
Ideally, we would have a prediction tool that could be used as early as possible in
pregnancy and be repeated throughout for an updated risk assessment. This would allow
women’s antenatal care to be tailored to their risk from early pregnancy. This was not
possible in this study, as we have only one sample taken at 26–28 weeks’ gestation in
BiB. Furthermore, all three of the studies used here were selected, non-random samples
(Figure 5A–C). The models that we found to improve the prediction of pregnancy-related
disorders need to be further tested on blood samples measured early in pregnancy and
random samples of general populations of pregnant women. An interesting avenue for
exploration would be to explore the relationship between metabolomic markers and the
time of onset for the pregnancy-related disorders in this paper.
4. Materials and Methods
4.1. Participants
BiB is a population-based prospective birth cohort that recruited 12,453 women who
had 13,776 pregnancies. Full details of the study methodology were reported previ-
ously [32]. In brief, most women were recruited at their oral glucose tolerance test (OGTT)
at approximately 26–28 weeks’ gestation, which is offered to all women booked for delivery
at Bradford Royal Infirmary, except those with known diabetes. Eligible women had an
expected delivery between March 2007 and December 2010. Bradford, in the North of
England, is one of the most deprived cities in the UK. In BiB, most of the obstetric pop-
ulation consists of women of White British or Pakistani origin (together accounting for
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81%). Ethical approval for the study was granted by the Bradford National Health Service
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association study; EDTA, ethylenediaminetetraacetic acid; HDP, hypertensive disorders of pregnancy; GD, gestational 
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Figure 5. Born in Bradford flowchart: the selection of participants for mass spectrometry metabolomic
profiling in the Born in Bradford 1000 (A) and 2000 (B). Abbreviations: MS, mass spectrometry; BiB,
Born in Bradford; GWAS, genome-wide association study; EDTA, ethylenediaminetetraacetic acid;
HDP, hypertensive disorders of pregnancy; GD, gestational diabetes; GHT, gestational hypertension;
PE, pre-eclampsia, PTB, preterm birth; CA, congenital anomaly; SB, still birth. (C) Illustrating the flow
of participants into the Metabolon datasets ((A) BiB 1000, (B) BiB 2000 and (C) POPs (n = 923) cohorts).
Abbreviations: MS, mass spectrometry; BiB, Born in Bradford; GWAS, genome-wide association
study; EDTA, ethylenediaminetetraacetic acid; HDP, hypertensive disorders of pregnancy; GDM,
gestational diabetes; GHT, gestational hypertension; PE, pre-eclampsia, PTB, preterm birth; sPTB,
spontaneous preterm birth; CA, congenital anomaly; SB, still birth; FGR, fetal growth restriction; GA,
gestational age. (A,B) were taken from our data note by Taylor et al. [33] with permission.
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The BiB metabolomics data have been described in detail previously in a data note [33].
In brief, 3000 women were selected for plasma MS metabolomic profiling using samples
taken at 26–28 weeks’ gestation [32]. These 3000 women had profiling in two separate
sub-samples of 1000 women and 2000 women. There was no participant overlap. Dataset 1
was completed in December 2017 and consisted of 1000 mother (pregnancy) and offspring
(cord blood) pairs. These were randomly sampled from pairs where both had a suitable
sample for analyses and belonged to one of the two main ethnic groups in BiB (Pakistani
or White British) (Figure 5A,B and Figure S1a). Only the maternal pregnancy metabolites
are used in this study. Dataset 1 is referred to as “BiB 1000”. Dataset 2 (“BiB 2000”) was
completed in December 2018 and consisted of 2000 mothers (Figure 1B and Figure S1b)
selected using a case-cohort design, including cases of GDM, PE, GHT, SGA, LGA, PTB,
stillbirths and congenital anomalies, together with a randomly selected sub-cohort of the
whole eligible cohort [28]. BiB 2000 was used for training the prediction models and the
BiB 1000 for testing them.
External validation was undertaken in POPs, a prospective cohort study of unselected
nulliparous women [19]. Those eligible were recruited at the Rosie Hospital, Cambridge,
U.K., between January 2008 and July 2012. Cambridge is an affluent city in eastern England,
and participants in POPs are nulliparous and mostly of White European origin. Ethical
approval was obtained from the Cambridgeshire Research Ethics Committee (reference
number 07/H0308/163). All study participants gave written informed consent. POPs also
utilises a case-cohort design, previously described elsewhere (Figure S1c) [19,28]. Only
singleton pregnancies were included in this study.
4.2. Metabolomic Predictors
The untargeted MS analysis of BiB and POPs samples was performed at Metabolon,
Inc. (Durham, NC, USA) using a modification of a previously described ultra-performance
liquid chromatography (UPLC)–mass spectrometry (MS) method (UPLC-MS/MS) [27,28].
The platform consisted of four independent UPLC-MS/MS methods. This method pro-
vides relative quantification of >1000 metabolites in key classes: amino acids, carbohy-
drates, lipids, nucleotides, carbon metabolism, vitamins, xenobiotics and novel unidentified
metabolites. Metabolite concentrations were quantified using the area under the curve of
primary MS ions and were expressed as the means of the medians (MoM) value for all
batches processed on the given day. Metabolon data are provided in a quantified (scaled)
data set. Samples from the BiB 1000, BiB 2000 and POPs were run in different batches and
are all analysed separately in this study (BiB 2000 for training, BiB 1000 for testing and
POPs for external validation). In BiB, MS analyses were undertaken on ethylenediaminete-
traacetic acid (EDTA) plasma taken around 26–28 weeks’ gestation. In POPs, MS analyses
were undertaken on maternal serum samples from 12, 20, 28 and 36 weeks of gestation. In
this study, we used the 28-week gestation timepoint for our external validation, as this best
matched the gestation of the BiB samples. Previous work has shown that reproducibility
in both serum and plasma is good. If the same sample procedures are used, either matrix
should yield similar results [34]. Further information on the metabolomic data in both
cohorts has been published previously [28,33,35]. The participant selection workflows are
available in Figure S1a–c. We included 718 metabolites in our models, which is the number
of metabolites available in BiB 1000, BiB 2000 and POPs. A full list of the metabolites and
their pathways included in this study as predictors is provided in Table S1.
4.3. Risk Factor Predictors
We compared metabolomic prediction models to models of risk factor predictors that
are routinely collected in antenatal care: maternal age, early pregnancy BMI, parity, ethnic-
ity and smoking during pregnancy. This information was collected during recruitment or
extracted from clinical records. In BiB, data on parity and weight were extracted from the
first antenatal clinic records (around 12 weeks of gestation). Weight (kg, Seca 2 in1 scales,
Harlow Healthcare Ltd., London, UK) and height (cm) were measured using established
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protocols at recruitment and used to calculate BMI. Parity was dichotomised as having ex-
perienced one or more previous pregnancy ≥24 weeks gestation or no previous pregnancy.
Data on age, ethnicity and smoking were obtained from questionnaires administered by
the BiB research fieldworkers at recruitment. These fieldworkers included people fluent in
the common languages used by women undergoing antenatal care in Bradford at the time
of recruitment, including Urdu and Mirpuri. In BiB, ethnicity was self-reported or obtained
from primary care medical records and categorised as either White British or Pakistani (the
only two ethnic groups who had metabolomic profiling and who together include over
85% of the BiB mothers).
In POPs, only nulliparous women were recruited [36–38]. Weight measured at recruit-
ment (~12 weeks) was used for the calculation of BMI, and maternal age was defined as
age at recruitment. Maternal height was measured at ~20 weeks. Maternal ethnicity and
smoking were self-reported using a questionnaire at ~20 weeks in POPs, and ethnicity was
categorised as White or non-White for the present analysis. In both studies, smoking was
dichotomised as any smoking during pregnancy.
4.4. Outcomes
We examined predictive discrimination for six pregnancy-related disorders: GDM,
GHT, PE, SGA, LGA and sPTB. In BiB, blood pressure and proteinuria measurements taken
at any time during pregnancy were extracted from medical records. In BiB, GHT was
defined as a new onset of elevated blood pressure (systolic blood pressure ≥140 mmHg or
greater and/or diastolic blood pressure ≥90 mmHg or greater) after 20 weeks’ gestation
on two or more occasions. In POPs, cases of GHT were not identified for inclusion in the
case-cohort sub-sample on whom metabolites were assayed. Consequently, we were unable
to explore the external validation of our GHT prediction models. In BiB, PE was defined
as GHT plus clinically significant proteinuria, defined as 1 or greater ‘+’ on the reagent
strip reading (equivalent to 30 mg/mmol) or greater on the spot urine protein/creatinine
ratio (4). In POPs, PE was defined according to the 2013 American College of Obstetricians
and Gynaecologists (ACOG) guidelines [28,39]. The selection of cases did not include
non-severe superimposed PE associated with delivery at term, meaning PE in POPs likely
reflects a somewhat more severe group than in BiB. In BiB, GDM was defined according to
modified World Health Organization (WHO) definition used in clinical practice at the time:
fasting glucose≥ 6.1 mmol/L or 2 h post-load glucose≥ 7.8 mmol/L [5]. In POPs, between
2008 and 2010, GDM diagnosis was based on diagnostic criteria adapted from the WHO
recommendations: fasting, 1 h and 2 h glucose levels of ≥ 6.1 mmol/L, ≥ 10.0 mmol/L
or ≥ 7.8 mmol/L, respectively. From 2011 onwards, these were replaced locally with
diagnostic criteria adapted from the International Association of Diabetes and Pregnancy
Study Groups’ recommendations: fasting, 1 h and 2 h glucose levels of ≥ 5.3 mmol/L, ≥
10.0 mmol/L or ≥ 8.5 mmol/L, respectively [40].
In both studies, we used the Hadlock formula to derive gestational age and sex
standardised birthweight percentiles as previously described [41,42]. SGA was defined
as <5th percentile birth weight (being a more accurate measure of fetal growth restriction
than the conventional 10th percentile) and LGA as ≥90th percentile birthweight. In both
cohorts, sPTB was defined as the spontaneous onset of labour (i.e., without medical or
surgical induction or elective Caesarean section) before 37 completed weeks of gestation.
In POPs, there was additional criteria that delivery occurred after 24 completed weeks of
gestation. Whilst this specific criterion was not applied to BiB, no births before 24 weeks
gestation were included in the metabolomic profiling.
4.5. Statistical Analysis
All of the statistical analysis was performed in R 3.5.1, R.1.3.1 or STATA 15.1. In
POPs, prior to this paper’s analysis, one woman’s BMI was imputed by sample mean
and 15 women’s ethnicity was imputed by the most common category (White), since
the proportion of missing values in these variables was very small. Aside from these
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imputations, all data were complete, and any participants with missing data on risk factors
or outcomes were excluded from the analysis.
4.6. Comparison Groups in the Case-Cohort BiB 2000 and POPs
BiB 2000 and POPs sampled participants for metabolomic analyses using a case-cohort
design, which increases statistical power (by including all cases for each outcome). This
allows the analysis of associations of metabolites with multiple outcomes, with the com-
parison group for each cohort being the equivalent of a random sample of the underlying
cohort [42]. In a case-cohort design, we only use the non-cases of the given outcome from
the random sub-cohort as controls. Therefore, we remove oversampled ‘cases’ that are not
a case of interest for this study.
4.7. Main Analyses
Only metabolites present in all three datasets (BiB 1000, 2000 and POPs) were included
in the prediction models (n = 718). Prior to analysis, scaled and imputed (using the mean
of the medians) metabolite values were log transformed and then converted to standard
deviation (SD) units by subtracting the sample mean from their logged value and dividing
by the sample SD of the logged values, within the prediction model. This results in some
metabolites with very little variance. We applied a variance threshold in BiB of more than
440 unique values. This reduced the number of metabolites in the dataset from 1371 to
1074 in the BiB 1000 and 1241 to 1152 in the BiB 2000. We then only included metabolites
present in all three datasets (BiB 1000, 2000 and POPs) and included these in the prediction
models (n = 718). In the training dataset (BiB 2000), we optimised the elastic net penalized
regression fit by tuning model hyperparameters, alpha and lambda, using 10-fold cross
validation implemented with the caret package in R [43]. The hyperparameter tuning tests
out different values of alpha and lambda and chooses a combination of both that results in
the best performing model. Optimal hyperparameter value combinations were selected that
maximised the cross-validated AUCs in the training set. The lambda parameter constrains
the sum of the individual predictor coefficient values, performing feature selection. Feature
selection is the process where the most relevant predictors, or features, are chosen for
inclusion in a prediction model. Thus, non-informative predictors are removed from the
final prediction model. Out-of-sample prediction performance was further assessed by
AUC and calibration slopes in both the BIB 1000 test set and external validation in POPs.
In all, we assessed the ability to discriminate pregnancy-related disorders by comparing
AUC values for three models: (1) the established risk factors model, (2) the MS-derived
metabolites model and (3) the combined established risk factors and metabolites model.
4.8. Additional Analysis
When studying preterm birth, POPs focused on those cases that were due to spon-
taneous preterm labour (sPTB). For concordance, sPTB was also used in BiB despite the
availability of cases of non-spontaneous preterm birth. However, in an additional analy-
sis, we also trained and tested a model for predicting any PTB, defined as any delivery
< 37 completed weeks in the BiB cohorts irrespective of the onset of labour.
We wanted to see whether we could create an accurate prediction model for ‘any’
pregnancy-related disorder. We created a binary variable of ‘any’ of GDM, GHT, PE,
LGA, SGA or sPTB cases compared with women who had experienced none of those. As
in the main analysis, for these additional analyses, we trained the models in BiB 2000
and tested them in BiB 1000, assessed discrimination using AUC and calibration using
calibration slopes.
5. Conclusions
To conclude, our results suggest metabolomics combined with established risk factors
can improve the prediction of GDM and LGA. We validated our findings in an indepen-
dent cohort. However, we acknowledge the need to validate these findings in a large
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independent sample of unselected pregnant women and examine their accuracy when mea-
sured earlier on in pregnancy. These findings show promise for the use of blood-derived
metabolomics to improve the prediction of common pregnancy complications. Further
validation would support the development of the tool using only the specific metabolites
(rather than incurring the cost of the full panel) and testing its effectiveness in practice.
Thus, our findings provide a promising evidence base for further research with the aim of
being able to tailor antenatal care for women at risk of GDM and LGA.
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